Advanced electrotransfer for IL-12 gene immunotherapy in melanoma: Challenges and possibilities [0.03%]
用于治疗黑色素瘤的IL-12基因电转疗法定量与可能面临的挑战
Yasuharu Niwa,Junetsu Igarashi
Yasuharu Niwa
Ravi Dhital,Marcelo S F Pereira
Ravi Dhital
An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells' stemness features and migration [0.03%]
一种表达CXCR4拮抗剂的溶瘤疱疹病毒干扰胶质母细胞瘤干细胞特性及迁移能力
D&#x;arrigo Paolo,Dubois Maxime,Sanchez Gil Judit et al.
D&#x;arrigo Paolo et al.
Glioblastoma (GBM) is one of the most aggressive brain tumors. Despite the standard therapy, the survival from diagnosis remains dramatically low, especially due to tumor recurrence. Glioblastoma stem-like cells (GSCs) have been implicated ...
Targeted degradation of KRAS and induction of bystander effects by a modular bioPROTAC [0.03%]
模块化bioPROTAC特异性降解KRAS并诱导旁观者效应
Shojiro Inano,Akifumi Takaori-Kondo,Takako Nakajima
Shojiro Inano
Targeted protein degradation is a promising strategy for addressing oncogenic drivers that are difficult to inhibit with small molecules, such as KRAS. While bioPROTACs expand the range of targetable proteins, their clinical translation is ...
Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models [0.03%]
溶细胞新城疫病毒介导的CD47阻断在黑色素瘤和胰腺癌模型中的作用
Jacob G E Yates,Lily Chan,Alyssa E Bogle et al.
Jacob G E Yates et al.
Newcastle disease virus (NDV) exhibits strong immunostimulatory activity and a favorable safety profile, but its moderate monotherapy efficacy may be improved through combination therapies. Although NDV selectively infects and lyses tumor c...
Clinical translation of TLR agonist-modified silicified cancer cell therapy supported by humanized mouse models [0.03%]
人源化小鼠模型支持的TLR激动剂修饰硅化癌细胞治疗的临床转化
Mara P Steinkamp,Danielle Burke,Madigan Morrison et al.
Mara P Steinkamp et al.
Humanized patient-derived xenograft (huPDX) mouse models are crucial for evaluating the clinical translation of new immune therapeutics. Silicification of cancer cells renders the cells non-viable with enhanced stability and silica surface ...
Rare but not forgotten: Therapeutic advancements for rare childhood cancers [0.03%]
罕见而不被遗忘：儿童罕见癌症治疗进展
Jacquelyn N Crane,Urania Dagalakis,Robyn D Gartrell et al.
Jacquelyn N Crane et al.
Cancers in children represent less than 1% of all new cases of cancer. While all cancers are rare during childhood, certain types are particularly rare. Multi-institutional pediatric trials and coordinated efforts between pediatric and adul...
Functional characterization of tumor-specific CRISPR-directed gene editing as a combinatorial therapy for the treatment of solid tumors [0.03%]
肿瘤特异性CRISPR定向基因编辑的功能表征及其与其它疗法联合治疗实体瘤的研究
Kelly H Banas,Pawel A Bialk,Natalia Rivera-Torres et al.
Kelly H Banas et al.
As we pursue clinical applications for CRISPR-directed gene editing in overcoming resistance to anticancer drugs, we have focused on genetic disruption of the transcription factor, NRF2, a master regulator of cellular stress and detoxificat...
Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy [0.03%]
ABTB2的胰腺癌治疗新靶点作用及功能机制研究
Nan Lyu,Olamide T Olaoba,Qiongling Wang et al.
Nan Lyu et al.
BTB/POZ domain-containing proteins are increasingly recognized for their context-dependent roles in cancer, acting as either tumor suppressors or oncogenic drivers depending on the cancer type. Among them, the function of ankyrin repeat and...
Tackling cancer heterogeneity with systemically delivered oncolytic adenoviruses transcriptionally targeted with hybrid promoters [0.03%]
利用杂合启动子系统传递的溶瘤腺病毒克服肿瘤异质性
Maria A Russo-Maenza,Gregorio D Ríos,Lourdes M Hirschson Alvarez Prado et al.
Maria A Russo-Maenza et al.
Tumor escape driven by cancer heterogeneity is a hallmark of human malignancies. Oncolytic adenoviruses (OAds) are transcriptionally targeted to selectively replicate in cancer cells through the use of tumor-specific promoters (TSPs). The a...